Schwab Charles Investment Management Inc. lifted its position in IQVIA (NYSE:IQV) by 0.8% during the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 575,608 shares of the medical research company’s stock after purchasing an additional 4,570 shares during the quarter. Schwab Charles Investment Management Inc. owned about 0.28% of IQVIA worth $56,473,000 at the end of the most recent quarter.
Several other institutional investors have also recently added to or reduced their stakes in IQV. Winslow Evans & Crocker Inc. bought a new position in shares of IQVIA in the fourth quarter worth $123,000. Focused Wealth Management Inc bought a new position in shares of IQVIA in the fourth quarter worth $166,000. Valeo Financial Advisors LLC bought a new position in shares of IQVIA in the fourth quarter worth $170,000. IFP Advisors Inc bought a new position in shares of IQVIA in the fourth quarter worth $200,000. Finally, Livforsakringsbolaget Skandia Omsesidigt bought a new position in shares of IQVIA in the fourth quarter worth $209,000. 92.43% of the stock is currently owned by hedge funds and other institutional investors.
IQVIA opened at $101.63 on Friday, according to MarketBeat Ratings. The company has a quick ratio of 1.16, a current ratio of 1.16 and a debt-to-equity ratio of 1.22. IQVIA has a 12-month low of $82.83 and a 12-month high of $110.67. The stock has a market cap of $21.05 billion, a price-to-earnings ratio of 21.00, a price-to-earnings-growth ratio of 1.70 and a beta of 0.64.
IQVIA (NYSE:IQV) last posted its quarterly earnings results on Wednesday, May 2nd. The medical research company reported $1.34 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.27 by $0.07. IQVIA had a net margin of 13.07% and a return on equity of 13.35%. The business had revenue of $2.56 billion during the quarter, compared to analyst estimates of $2.42 billion. IQVIA’s revenue was up 34.1% on a year-over-year basis. sell-side analysts predict that IQVIA will post 5.06 earnings per share for the current fiscal year.
Several research analysts have recently weighed in on the stock. SunTrust Banks reaffirmed a “hold” rating and issued a $110.00 price target on shares of IQVIA in a report on Monday, January 22nd. Mizuho set a $97.00 target price on shares of IQVIA and gave the stock a “hold” rating in a research report on Wednesday, January 24th. Zacks Investment Research upgraded shares of IQVIA from a “strong sell” rating to a “hold” rating in a research report on Friday, March 23rd. Royal Bank of Canada set a $118.00 target price on shares of IQVIA and gave the stock a “buy” rating in a research report on Thursday, February 15th. Finally, JPMorgan Chase upped their target price on shares of IQVIA from $115.00 to $120.00 and gave the stock an “overweight” rating in a research report on Thursday, February 15th. Seven analysts have rated the stock with a hold rating, twelve have given a buy rating and one has assigned a strong buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average target price of $110.47.
In other IQVIA news, insider Robert Parks sold 896 shares of the company’s stock in a transaction dated Thursday, March 15th. The shares were sold at an average price of $105.73, for a total transaction of $94,734.08. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider James H. Erlinger III sold 10,000 shares of the company’s stock in a transaction dated Monday, February 26th. The shares were sold at an average price of $100.00, for a total transaction of $1,000,000.00. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 12,527 shares of company stock valued at $1,257,834. Company insiders own 6.00% of the company’s stock.
IQVIA Company Profile
IQVIA Holdings Inc provides integrated information and technology-enabled healthcare services in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Commercial Solutions, Research & Development Solutions, and Integrated Engagement Services. The Commercial Solutions segment offers a range of cloud-based applications and related implementation, real-world insights, and reference information services; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services.
Receive News & Ratings for IQVIA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IQVIA and related companies with MarketBeat.com's FREE daily email newsletter.